ArticleMolecular biology reports2026
Axonal protection by nicotinamide riboside with the SIRT1-AMPK pathway in TNF-induced optic nerve damage.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNicotinamide riboside (NR) is an NAD+ precursor and is reported to upregulate NAD+ levels in several tissues. We previously demonstrated that NR exhibited protection against axon loss induced by tumor necrosis factor (TNF) with upregulation of SIRT1 and enhancement of autophagy. We recently found that NR upregulated phosphorylated adenosine monophosphate-activated protein kinase (p-AMPK) protein in the optic nerve. The present study aimed to examine whether a SIRT1 inhibitor prevents axonal protection by NR and alters p-AMPK expression. METHODS AND
resultsRats were given intravitreal injection of a SIRT1 inhibitor prior to simultaneous injection of NR and TNF. The SIRT1 inhibitor alone or NR alone group was also made. SIRT1 and p-AMPK expression in optic nerve was investigated by immunoblot analysis. We examined the localization of SIRT1 and p-AMPK in the retina and optic nerve. Morphometric analysis showed axonal protection by NR in TNF-induced axon loss, and this protective effect was significantly prevented by the SIRT1 inhibitor. The SIRT1 inhibitor alone did not alter axon numbers significantly compared with the control group. The SIRT1 inhibitor significantly decreased p-AMPK levels in optic nerves in NR plus TNF-treated eyes. On the other hand, the SIRT1 inhibitor alone did not alter p-AMPK levels. Co-localization of SIRT1 and p-AMPK was observed in the retina and optic nerves in NR-treated eyes.
conclusionsSIRT1 exists upstream of AMPK, and axonal protection of NR is associated with the SIRT1-AMPK pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.